• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Sexual, Gender Minorities With Chronic Skin Diseases More Likely to Face Barriers to Care

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Oct. 3, 2023 -- Sexual and gender-minority (SGM) patients with chronic inflammatory skin diseases (CISDs) are more likely to experience cost and noncost barriers to care, according to a study published online Sept. 27 in JAMA Dermatology.

Michael R. Nock, from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a cross-sectional study of health care access and utilization survey data to compare the prevalence of cost and noncost barriers to care among SGM and non-SGM adult patients with CISDs. Data were included for 19,743 patients with CISDs: 1,877 SGM patients and 17,866 non-SGM patients.

The researchers found that SGM patients with CISDs were significantly more likely to delay specialist care, mental health care, and filling a prescription because of cost compared with non-SGM patients (adjusted odds ratios, 1.23, 1.62, and 1.30, respectively). Compared with non-SGM patients, SGM patients with CISDs were significantly more likely to delay care due to transportation issues (adjusted odds ratio, 1.49) and not having a health care practitioner who shares the same background with regard to race and ethnicity, religion, native language, sexual orientation, and gender identity (adjusted odds ratio, 1.39). SGM patients with CISDs were also more likely to report not always being treated with respect by their health care practitioners compared with non-SGM patients (adjusted odds ratio, 1.47).

"Dermatologists and other health care practitioners caring for SGM patients with CISDs have an important role in helping to address these barriers and larger systemic issues for SGM patients at both the patient and system levels," the authors write.

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.